Patents Represented by Attorney, Agent or Law Firm Elliott Korsen
  • Thiazolyl compounds useful as kinase inhibitors
    Patent number: 8343999
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: January 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Marco Dodier, Stephan Roy, Kurt Zimmermann, Xiaopeng Sang, Mark D. Wittman, David R. Langley, Ramkumar Rajamani
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8268998
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as anticancer agents.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: September 18, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ping Chen
  • 1,6-dihydro-1,3,5,6-tetraaza--indacene based tricyclic compounds and pharmaceutical compositions comprising same
    Patent number: 8268855
    Abstract: The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: September 18, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: William J. Pitts, James Kempson, Junqing Guo, Jagabandhu Das, Charles M. Langevine, Steven H. Spergel, Scott Hunter Watterson
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8263765
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: September 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Kurt Zimmermann, Xiaopeng Sang
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8212031
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: July 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Dolatrai M. Vyas
  • JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
    Patent number: 8202881
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: June 19, 2012
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ashok V. Purandare, James W. Grebinski, Amy Hart, Jennifer Inghrim, Gretchen Schroeder, Honghe Wan
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8198438
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anti-cancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: June 12, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anthony J. Sampognaro, Mark D. Wittman
  • Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
    Patent number: 8148522
    Abstract: The invention relates to 2,4-dibromoropyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing the intermediate.
    Type: Grant
    Filed: January 2, 2008
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventor: Upender Velaparthi
  • Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates
    Patent number: 8148523
    Abstract: The invention relates to 4-chloro-2-iodopyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing said intermediate.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventor: Brian E. Fink
  • Thiazolyl compounds useful as kinase inhibitors
    Patent number: 8148400
    Abstract: The invention provides compounds of formula II: and pharmaceutically acceptable salts thereof. The formula II thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anne Marinier, Claude A. Quesnelle, Marco Dodier, Stephan Roy, Patrice Gill, Mark D. Wittman, David R. Langley
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7982033
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as anticancer agents.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: July 19, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ping Chen
  • Crystalline forms of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester
    Patent number: 7932383
    Abstract: Crystalline form, Form N-1, of [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising the Form N-1 of Compound I as well as a method of using the Form N-1 of Compound I in the treatment of cancer and other proliferative diseases.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: April 26, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventor: John E. Thornton
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7879855
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: February 1, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Macrolactams by engineered biosynthesis
    Patent number: 7855192
    Abstract: Macrolactams are made by feeding aromatic amino acids as replacement starter units to a mutant strain of the geldanamycin-producing microorganism Streptomyces hygroscopicus var. geldanus NRRL 3602, wherein the gene cluster encoding enzymes for the biosynthesis of the natural starter unit 3-amino-5-hydroxybenzoic acid has been deleted.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: December 21, 2010
    Assignee: Kosan Biosciences, Inc.
    Inventors: Gary W. Ashley, Hugo Menzella, Janice Lau Wee, John R. Carney
  • Aminopyrazole kinase inhibitors
    Patent number: 7851500
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: December 14, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Marco Dodier, Claude A. Quesnelle, Anne Marinier
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7846931
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: December 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Inhibitors of kinases
    Patent number: 7820814
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: October 26, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Zhen-Wei Cai, Ligang Qian, Stephanie Barbosa, Louis Lombardo, Jeffrey Robl
  • Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester
    Patent number: 7671199
    Abstract: The invention relates to an improved process for preparing [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester of the formula: Compound I has been shown to be useful for the treatment of certain types of cancer.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: March 2, 2010
    Assignee: Britsol-Myers Squibb Company
    Inventors: Gerard A. Crispino, Mourad Hamedi, Thomas L. LaPorte, John E. Thornton, Jaan A. Pesti, Zhongmin Xu, Paul C. Lobben, David K. Leahy, Jale Muslehiddinoglu, Chiajen Lai, Lori Ann Spangler, Robert P. Discordia, Francis S. Gibson
  • 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
    Patent number: 7648976
    Abstract: Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxygeldanamycin (17-AAG).
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: January 19, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter J. Licari, Timothy Leaf, Ruchir P. Desai, Jorge L. Galazzo, Greg O. Buchanan, Stephen William Watt, Alexander Redvers Eberlin, Robert Arslanian
  • Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
    Patent number: 7619083
    Abstract: The invention relates to 2,4-dichloropyrrolo[1,2-f][1,2,4]triazines, which are intermediates useful in preparing at least one 2,4-disubstituted pyrrolotriazine compound, and at least one method for making such intermediates.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: November 17, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Harold Mastalerz, Guifen Zhang